Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AIM ImmunoTech ( (AIM) ) just unveiled an update.
AIM ImmunoTech Inc. announced the appointment of David I. Chemerow to its Board of Directors, effective February 24, 2025. Mr. Chemerow brings over 40 years of experience in finance, accounting, and operations across multiple industries, having held significant roles at Comscore, Inc. and Rentrak Corporation. His appointment is expected to enhance AIM’s strategic direction as the company continues to advance its mission in the immuno-pharma space. Additionally, AIM has amended its bylaws to reduce the quorum for stockholder meetings from 40% to 33 and 1/3%.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The company’s lead product is Ampligen, a first-in-class investigational drug with broad spectrum activity in clinical trials for globally important cancers, viral diseases, and disorders of the immune system.
YTD Price Performance: -44.09%
Average Trading Volume: 938,617
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.52M
See more insights into AIM stock on TipRanks’ Stock Analysis page.